Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of who...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Grimshaw, Miguel, Ceballos-Liceaga, Santa Elizabeth, Hernández-Vanegas, Laura E., Núñez, Isaac, Hernández-Valdivia, Noé, Carrillo-García, Daniel Amado, Michel-Chávez, Anaclara, Galnares-Olalde, Javier Andrés, Carbajal-Sandoval, Guillermo, del Mar Saniger-Alba, María, Carrillo-Mezo, Roger A., Fragoso-Saavedra, Sergio, Espino-Ojeda, Alba, Blaisdell-Vidal, Carlos, Mosqueda-Gómez, Juan Luis, Sierra-Madero, Juan, Pérez-Padilla, Rogelio, Alomía-Zegarra, José Luis, López-Gatell, Hugo, Díaz-Ortega, José Luis, Reyes-Terán, Gustavo, Arauz, Antonio, Valdés-Ferrer, Sergio Iván
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213977/
https://www.ncbi.nlm.nih.gov/pubmed/34147649
http://dx.doi.org/10.1016/j.clim.2021.108786
Descripción
Sumario:mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.

Ejemplares similares